Teva Pharmaceutical Industries
TEVA
Positions held
Your positionsTEVA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Teva's competitive positioning in the generic drug market allows it to leverage cost advantages and scale, which is critical for maintaining profitability in a price-sensitive industry.
- Teva's revenue increased by 4% compared to the prior quarter, reaching $4.1 billion.
- The gross margin improved to 52%, up from 49.5% in the previous quarter.
- The pharmaceutical industry is facing regulatory pressures that could impact pricing strategies and profit margins for companies like Teva.
- Teva reported a net income loss of $576 million in Q2 2026, indicating ongoing financial challenges.
- The operating margin has significantly compressed to 3.6%, down from 19.1% in the previous quarter.
Fundamentals
| Market cap | $45.78B | Enterprise value | $58.98B | Trailing P/E | 65.42 | Forward P/E | 12.72 |
| PEG | 0.71 | Price / book | 5.90 | Beta | 0.82 | Dividend yield | 0.00% |
| Revenue growth | -0.8% | Earnings growth | — | Gross margin | 52.5% | Operating margin | 4.0% |
| Profit margin | 4.1% | ROE | 9.7% | ROA | 5.1% | Debt / equity | 2.18 |
| Current ratio | 0.88 | Free cash flow | $2.22B | Analyst recommendation | buy | Mean target | $45.30 |
| 52w high | $40.79 | 52w low | $18.83 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $4.1B | $4.0B | $4.7B | $4.5B | $4.2B | — |
| Op margin | 3.6% | 19.1% | 26.9% | 24.0% | 21.5% | — |
| Net income | -$576M | $369M | $480M | $433M | $282M | — |
| Gross margin | 52.0% | 49.5% | 56.4% | 51.4% | 50.3% | — |
| Gross profit | $2.2B | $2.0B | $2.7B | $2.3B | $2.1B | — |
| Operating income | $149M | $759M | $1.3B | $1.1B | $899M | — |
- Revenue +4% vs prior quarter ($4.1B vs $4.0B).
- Gross margin 52% (was 49.5% prior quarter).
- Operating margin compressed to 3.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $17.3B | $16.5B | $15.8B | $14.9B |
| Op margin | 22.9% | 20.3% | 20.2% | 18.0% |
| Net income | $1.4B | -$1.6B | -$559M | -$2.4B |
| Gross margin | 51.8% | 48.7% | 48.2% | 46.7% |
| Gross profit | $8.9B | $8.1B | $7.6B | $7.0B |
| Operating income | $4.0B | $3.4B | $3.2B | $2.7B |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Teva (TEVA) Stock Fair Value Rises As Analysts Back CNS Transformation
2026-10-07 · QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
2026-10-05 · What You Need to Know Ahead of Deckers Outdoor’s Earnings Release
2026-10-02 · Update: Teva, Samsung Bioepis Partner to Develop, Commercialize Biosimilar Candidates
2026-10-01 · Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls
2026-10-01 · Branded Medicines and Pipeline Successes Drive Teva Pharmaceutical Industries’ (TEVA) Margin Expansion
2026-10-01 · TD Cowen Initiates Teva Pharmaceutical Industries at Buy With $55 Price Target
2026-10-01 · Teva, Samsung Bioepis Partner to Develop and Commercialize Biosimilar Candidates
Price (daily)
Full chart · RSI · MACD · patterns